The Drug Being Fast-Tracked as a Depression Cure Is Quietly Costing Some People Their Bladders — and No One in the System Saw It Coming

By 2016, Amy Massey’s years of heavy ketamine use had scarred her bladder so badly that doctors scheduled it for removal. Not medication, not tapering, not a treatment plan. Surgery, as the only option left. What actually changed her outcome wasn’t a drug service. It was a YouTube video made by a harm reduction advocate named Mat Southwell, according to Filter’s reporting. She tried what he described. Her symptoms improved enough that the surgery got cancelled.

Sit with that for a second: a woman one appointment away from losing an organ found her way out through a stranger’s video, not the healthcare system that was supposed to catch her.

The same molecule getting fast-tracked into clinics as a breakthrough depression treatment is, outside that context, quietly destroying people — and the system built to help them doesn’t know what it’s looking at.

That’s the thesis, and it’s not a coincidence, it’s a gap. Ketamine is a dissociative — a drug that separates your sense of self from your body and surroundings, which is exactly why it works, carefully dosed, in a monitored clinical setting for treatment-resistant depression. Outside that room, in higher and more frequent doses, it’s a different drug entirely, one that can quietly wreck the bladder lining and rewire how badly you need it to feel normal. Filter reports the UK is now seeing children as young as 11 or 12 starting, showing up in pediatric urology wards by 13 or 14. Southwell doesn’t soften it: he calls the system’s response “intentional negligence,” and says ketamine “didn’t fit with the recovery model” clinicians already had, so nobody built one for it.

Massey knows that gap from the inside. “When you go to a drug service, there’s nothing on ketamine,” she told Filter. “They’re asking us the questions.” She now works alongside Southwell at Coact, training the same frontline workers who once had nothing to offer her. Her read on why services fail people using ketamine isn’t complicated: staff are “overwhelmed,” and by the time someone walks in the door, “the damage has already been done.”

If you’re the one still using and reading this instead of a clinician — you already knew that last part. You’ve probably sat across from someone whose script for helping you didn’t have a ketamine chapter in it.

Here’s where it gets interesting: the UK’s Advisory Council on the Misuse of Drugs just recommended, in January, against moving ketamine to the harshest legal category, concluding that longer sentences wouldn’t reduce use. That’s a real, defensible policy call. But it leaves the actual gap — untrained services, unrecognized symptoms, no protocol — exactly where it was. Nobody voted to fix that this year. Peers did it anyway. A Reddit community, r/KetamineAddiction, has grown past 10,500 members since 2021; a companion WhatsApp group launched in 2024 now supports more than 700 people across the UK, running sober meetups and informal check-ins that no commissioner funded. A moderator there, Mason Stillings, calls it “a lifeline” — mostly because it’s correcting a myth clinics never bothered to: that ketamine is somehow one of the “safe” ones.

The regulatory debate will keep running. The people fixing this in real time already found each other without waiting for it to end. Amy Massey kept her bladder because of a video, not a policy — and she’s spent every day since making sure the next person doesn’t have to find that video by accident.